Literature DB >> 1886446

The natural history of epistaxis in hereditary hemorrhagic telangiectasia.

O S AAssar1, C M Friedman, R I White.   

Abstract

The purpose of this retrospective study is to document the natural history of epistaxis in patients with hereditary hemorrhagic telangiectasia. A telephone questionnaire was administered to 73 patients who had been previously screened for pulmonary arteriovenous malformations (PAVMs). The incidence of epistaxis in this population was 93%, with a mean onset age of epistaxis of 12 years, a mean frequency of bleeding of 18 episodes per month, and a mean duration of bleeding of 7.5 minutes. More than 90% of patients experienced the onset of epistaxis before the age of 21 and symptoms were progressive with age. There were no differences in the age of onset, frequency of epistaxis, or duration of epistaxis between patients with PAVMs versus those without PAVMs. Although the natural history of epistaxis does not predict the presence or absence of pulmonary arteriovenous malformations, epistaxis is an early marker of the disease, hereditary hemorrhagic telangiectasia, and might guide screening for pulmonary and cerebral arteriovenous malformations in children of affected parents.

Entities:  

Mesh:

Year:  1991        PMID: 1886446     DOI: 10.1288/00005537-199109000-00008

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  48 in total

1.  An evaluation of the severity and progression of epistaxis in hereditary hemorrhagic telangiectasia 1 versus hereditary hemorrhagic telangiectasia 2.

Authors:  Benjamin N Hunter; Benjamin H Timmins; Jamie McDonald; Kevin J Whitehead; P Daniel Ward; Kevin F Wilson
Journal:  Laryngoscope       Date:  2015-09-15       Impact factor: 3.325

Review 2.  Diagnosis and Treatment of Hereditary Hemorrhagic Telangiectasia.

Authors:  Cameron Grigg; Daniel Anderson; James Earnshaw
Journal:  Ochsner J       Date:  2017

3.  Visceral manifestations of hereditary hemorrhagic telangiectasia.

Authors:  Daniel M Goodenberger
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

4.  Identification of Retinal Vascular Lesions Using Ultra-Widefield Angiography in Hereditary Hemorrhagic Telangiectasia Patients.

Authors:  Sampat Sindhar; Bliss E O'Bryhim; Jordan Licata; Jay F Piccirillo; Rajendra S Apte
Journal:  Ophthalmol Retina       Date:  2019-02-15

5.  Rare manifestations in a case of Osler-Weber-Rendu disease.

Authors:  Abhijai Singh; Vikas Suri; Sanjay Jain; Subhash Varma
Journal:  BMJ Case Rep       Date:  2015-01-05

6.  The value of screening for multiple arterio-venous malformations in hereditary hemorrhagic telangiectasia: a diagnostic study.

Authors:  Benedikt J Folz; Ana Cerra Wollstein; Heiko Alfke; Anja A Dünne; Burkard M Lippert; Konrad Görg; Hans-Joachim Wagner; Siegfried Bien; Jochen A Werner
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-12-17       Impact factor: 2.503

7.  Pial arteriovenous fistula in children as presenting manifestation of Rendu-Osler-Weber disease.

Authors:  R García-Mónaco; W Taylor; G Rodesch; H Alvarez; P Burrows; P Coubes; P Lasjaunias
Journal:  Neuroradiology       Date:  1995-01       Impact factor: 2.804

8.  Visceral manifestations in hereditary haemorrhagic telangiectasia type 2.

Authors:  S A Abdalla; U W Geisthoff; D Bonneau; H Plauchu; J McDonald; S Kennedy; M E Faughnan; M Letarte
Journal:  J Med Genet       Date:  2003-07       Impact factor: 6.318

Review 9.  Giant spinal perimedullary fistula in hereditary haemorrhagic telangiectasia: diagnosis, endovascular treatment and review of the literature.

Authors:  F Mont'Alverne; M Musacchio; V Tolentino; F Belzile; C Riquelme; A Tournade
Journal:  Neuroradiology       Date:  2003-10-14       Impact factor: 2.804

10.  Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia.

Authors:  Holly Boyer; Patricia Fernandes; Chap Le; Bevan Yueh
Journal:  Int Forum Allergy Rhinol       Date:  2015-02-02       Impact factor: 3.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.